Drug trial raises hopes for treatment of rectal cancer patients
Twelve patients with rectal cancer were included in the study. Patients received a new medicine called dostarlimab every three weeks for six months. Dostarmilab is an antibody that attacks cancer cells by exposing them to the immune system, which kills them. According to a research published recently in The New England Journal of Medicine, all … Read more